In two phase @ , double-blind trials ( EXPEDITION @ and EXPEDITION @ ) , we randomly assigned @ and @ patients , respectively , with mild-to-moderate Alzheimer 's disease to receive placebo or solanezumab ( administered intravenously at a dose of @ mg ) every @ weeks for @ months .